Clinical Trial

1st Line Durvalumab in PS 2 NSCLC Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the trial is to assess efficacy and safety of the treatment with durvalumab in PS 2 patients with treatment-naïve, locally advanced or metastatic, PD-L1 positive NSCLC who are considered unsuitable for combination platinum-containing therapy.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2018-08-07; most recent amendment 2025-08-14.
Status change: Recruiting → Active, Not Recruiting 2022-04-08
Status change: Suspended → Recruiting 2020-03-12
Status change: Recruiting → Suspended 2019-09-19
Status change: Not Yet Recruiting → Recruiting 2018-10-18
Trial Details
NCT Number NCT03620669
Lead Sponsor Swiss Cancer Institute
Conditions NSCLC Stage IV, NSCLC Stage IIIB
Enrollment 48 participants
Start Date 2018-12-04
Primary Completion 2023-01-19 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-15